Oral Weight-Loss Drugs: The New Frontier
Johannesburg News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
The weight-loss drug market is booming, with Novo Nordisk and Eli Lilly leading the charge. Lillys Foundayo is the second oral option, following Novos Wegovy. Both companies are developing next-level treatments, with Novos amycretin and CagriSema showing promising results. Lillys retatrutide also impressed with a twenty-eight point seven percent average loss. Obesity is a global crisis, driving demand for easier pills over weekly shots. Big Pharma is responding with massive deals and collaborations. Other players like Pfizer, Roche, Amgen, Viking, Merck, and Structure are also in the race, with orals showing twelve to fifteen percent loss in trials. This shift is reshaping the game, with late-stage pushes and fresh partnerships signaling bigger breakthroughs ahead.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/478e78123e972b53